Farmacoterapia en el síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica: ¿inmunoglobulina endovenosa, corticoides sistémicos, ciclosporina o inhibidores TNF-alfa? Actualización terapéutica SSJ/NET

• Herrera, P. ^[2] ; Sepúlveda Muñoz, A. ^[1] ; Jeldres Pulgar, A. ^[1] ; Rojas Muñoz, F. ^[1] ; Aedo Inostroza, G. ^[1]
  1. [1] Universidad de Santiago de Chile

     Universidad de Santiago de Chile

     Santiago, Chile

     
  2. [2] Servicio de Inmunología, Hospital Barros Luco Trudeau, Chile
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 36, Nº. 7 (AGOSTO-SEPTIEMBRE), 2021, págs. 466-471
• Idioma: español
• DOI: 10.1016/j.piel.2020.10.011
• Títulos paralelos:
  • Pharmacotherapy in Stevens Johnson syndrome and toxic epidermal NECROLYSIS: Intravenous immunoglobulin, systemic corticosteroids, cyclosporine or TNF-alpha inhibitors? SJS/NET therapeutic update
• Enlaces
  • Texto Completo Ejemplar
• Referencias bibliográficas
  • Wolfram Hötzenecker W. Eritema multiforme, síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. En: Bolognia J, Schaffer J, Cerroni...
  • García V. Cuidados intensivos en dermatología. Piel. 1992;7: 277–285.
  • Inamadar AC, Palit A. Acute skin failure: concept, causes, consequences and care. Indian J Dermatol Venereol Leprol. 2005; 71:379–385.
  • Schneider J, Cohen P. Review: Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic...
  • Saeed H, et al. Complications of Stevens–Johnson syndrome beyond the eye and skin. Burns. 2015. https://doi.org/10.1016/j. burns.2015.03.012.
  • Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective....
  • Whitney A. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica: patogénesis, manifestaciones clínicas y diagnóstico – UpToDate – actualización...
  • Duong TA, Valeyrie-Allanore L. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996–2011. https://doi.org/ 10.1016/S0140-6736(16)30378-6.
  • High WA. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica: manejo, pronóstico y secuelas a largo plazo. Up to Date. abr ; 2019 Actualización...
  • Bastuji-Garin S, Fouchard N, Bertocchi M, Revuz J, Roujeau JC, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epi- dermal necrolysis....
  • Valeyrie-Allanore L, Roujeau JC. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In: Goldsmith LA, Katz SI,...
  • Dorafshar AH, Dickie SR, Cohn AB, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr...
  • Creamer D, Walsh SA, Dziewulski P. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal Necrolysis in adults 2016....
  • Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal...
  • Valeyrie-Allanore L, Ingen-Housz-Oro S, Chosidow O, Wolkenstein P. French referral center management of Stevens-Johnson syndrome/toxic epidermal...
  • Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment...
  • Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with...
  • Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin...
  • Zhang S, Tang S, Li S, Pan Y, Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis:...
  • Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Intl Immunol. 2017;29(11):491–498.
  • Arumugam TV, Tang SC, Lathia JD, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement...
  • Emre S. Intravenous immunoglobulin treatment: where do dermatologists stand? Dermatol Ther. 2019:e12854.
  • Campione E, Marulli GC, Carrozzo AM, Chimenti MS. Highdose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal...
  • Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatol....
  • Zimmermann S, Sekula P. Systemic Immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis a systematic review...
  • Roujeau Jean-Claude, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the...
  • Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis:...
  • Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review...
  • Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev...
  • Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: linical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625–645.
  • Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and...
  • Ye L-P, Zhang C, Zhu Q-X. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens- Johnson syndrome...
  • Ng QX, Qing de Deyn MLZ. A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis. J In Ammation...
  • Kida Y, Kuwano K, Zhang Y, et al. Acholeplasma laidlawii upregulates granulysin gene expression via transcrip- tion factor activator protein-1...
  • Viard-Leveugle I, Gaide O, Jankovic D, et al. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through...
  • Wang F, Ye Y, Luo ZY, et al. Diverse expression of TNF-α and CCL27 in serum and blister of Stevens–Johnson syndrome/ toxic epidermal necrolysis....
  • Osabe M, Tajika T, Tohkin M. Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT...
  • Roujeau JC, et al. New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Investigat Dermatol. 2017;137: 2047–2049. https://doi.org/10.1016/j.jid.2017.07.828.